IP Library Granted Patent US 9,764,019
Granted Patent B2
US 9,764,019 · App. 14/903,377 · Granted Sep 19, 2017

Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease

Inventors: Kenya Honda (Yokohama, JP); Bernat Olle (Cambridge, MA); Koji Atarashi (Yokohama, JP); Takeshi Tanoue (Yokohama, JP); Hiroshi Ohno (Yokohama, JP); Shinji Fukuda (Yokohama, JP); Koji Hase (Yokohama, JP)
Assignees: Vedanta Biosciences, Inc.; RIKEN
A61K39/08A61K31/19A61K38/164A61K39/0008A61K45/06G01N33/56977A61K2039/577G01N2333/70539G01N2469/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,764,019
App. No.
14/903,377
Granted
Sep 19, 2017
Kind
B2
Abstract

Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent.

Claims (10)

1. A composition that induces proliferation and/or accumulation of regulatory T cells, the composition comprising:

(a) one or more short-chain fatty acid or short-chain fatty acid derivative; and

(b) one or more heat treated inactivated bacteria belonging to Clostridium Cluster IV, Clostridium Cluster XIVa, or Clostridium Cluster XVIII.

2. The composition of claim 1 , wherein (a) is selected from the group consisting of butyrate, isobutyrate, proprionate, acetate, tributyrin, pivaloyloxymethyl butyrate, and monoacetone glucose 3-butyrate.

3. The composition of claim 1 , wherein (a) is butyrate.

4. The composition of claim 1 , wherein (a) is a mixture of salts of butyrate, isobutyrate, propionate, and acetate.

5. The composition of claim 1 , further comprising a pH sensitive composition comprising an enteric polymer.

6. A pharmaceutical composition comprising the composition according to claim 1 and a pharmaceutically acceptable component.

7. A method for inducing proliferation and/or accumulation of regulatory T cells in an individual in need thereof, the method comprising administering, to the individual, the composition of claim 1 .

8. A method of treating, aiding in treating, reducing the severity of, or preventing at least one disease selected from an autoimmune disease, an inflammatory disease, an allergic disease, and an infectious disease in an individual in need thereof, the method comprising administering the composition of claim 1 to the individual.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2023
From: OXFORD FINANCE LLC
To: VEDANTA BIOSCIENCES, INC.
Reel/Frame 063440/0569 →
SECURITY INTEREST Recorded Apr 21, 2023
From: VEDANTA BIOSCIENCES, INC.
To: ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE
Reel/Frame 063406/0052 →
SECURITY INTEREST Recorded Dec 12, 2022
From: VEDANTA BIOSCIENCES, INC.
To: OXFORD FINANCE LLC
Reel/Frame 062115/0411 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2016
From: OLLE, BERNAT
To: VEDANTA BIOSCIENCES, INC.
Reel/Frame 038906/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2016
From: HONDA, KENYA; ATARASHI, KOJI; TANOUE, TAKESHI; OHNO, HIROSHI; FUKUDA, SHINJI; HASE, KOJI
To: RIKEN
Reel/Frame 038264/0696 →
Continuity (2)
Provisional Application 61844204 · Jul 9, 2013
Related Publication 20160144014A1 · May 26, 2016